BRAF和EGFR抑制剂联合用于<em>BRAF</em>突变型复发转移性结直肠癌PDXs模型的研究

王　英; 马　晗; 李文涛

doi:10.19401/j.cnki.1007-3639.2017.07.003

您当前的位置：

首页 >

文章列表页 >

BRAF和EGFR抑制剂联合用于BRAF突变型复发转移性结直肠癌PDXs模型的研究

更新时间：2025-12-31

- BRAF和EGFR抑制剂联合用于BRAF突变型复发转移性结直肠癌PDXs模型的研究
- BRAF inhibitor combined with EGFR inhibitor for PDXs model ofBRAFmutant recurrent and metastatic colorectal cancer
- 中国癌症杂志 2017年27卷第7期页码：533-537
- 作者机构：
  
  复旦大学附属肿瘤医院介入治疗科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
  
  国家重点研发计划(2016YFC0106203)。
- DOI：10.19401/j.cnki.1007-3639.2017.07.003
  中图分类号：
- 网络出版：2017-08-16，
  
  纸质出版：2017-08-16
- 稿件说明：
移动端阅览
王　英,马　晗,李文涛,等 . BRAF和EGFR抑制剂联合用于

王　英, 马　晗, 李文涛. BRAF inhibitor combined with EGFR inhibitor for PDXs model ofBRAFmutant recurrent and metastatic colorectal cancer[J]. China Oncology, 2017, 27(7): 533-537.
王　英,马　晗,李文涛,等 . BRAF和EGFR抑制剂联合用于 DOI： 10.19401/j.cnki.1007-3639.2017.07.003.

王　英, 马　晗, 李文涛. BRAF inhibitor combined with EGFR inhibitor for PDXs model ofBRAFmutant recurrent and metastatic colorectal cancer[J]. China Oncology, 2017, 27(7): 533-537. DOI： 10.19401/j.cnki.1007-3639.2017.07.003.

摘要

背景与目的：结直肠癌患者中BRAF基因突变的概率为5%~15%，临床预后明显差于无突变者。该研究将BRAF与表皮生长因子受体(epidermal growth factor receptor，EGFR)抑制剂联合用于BRAF V600E突变型复发转移性结直肠癌的患者来源异种移植(patient-derived xenografts，PDXs)模型，观察其安全性、可行性及疗效。方法：2016年1月—2016年12月，复旦大学附属肿瘤医院34例疑似结直肠癌术后复发或转移的患者利用CT引导下的穿刺活检方法获取组织标本，建立复发转移性结直肠癌的PDXs模型，筛选BRAF突变者传代培养至F2代进行药物实验，实验组分为BRAF抑制剂组(A组)、EGFR抑制剂组(B组)、BRAF和EGFR抑制剂联合组(C组)及安慰剂对照组(D组)。给药3周后处死实验动物，统计建模成功率及抑瘤率。结果：34例患者中共23例病理证实为结直肠癌复发或转移，成功建立16个PDX模型，建模成功率为69.6%(16/23)。共筛选出4例BRAF V600E基因突变者，成功建立4个BRAF突变型复发转移性结直肠癌的PDXs模型。实验组无明显药物毒性相关性死亡，实验组抑瘤率分别为21.57%、21.61%和66.81%，差异有统计学意义(P0.05)。结论：CT引导下的穿刺活检建立复发转移性结直肠癌的PDXs模型成功率高，针对EGFR和BRAF的双重打击治疗安全、可行，能够明显提高BRAF突变型结直肠癌的疗效。

Abstract

Background and purpose: The incidence of BRAF mutation ranged from 5% to 15% among colorectal cancer according to previous studies

and was associated with poor survival. To evaluate safety

feasibilityand efficiency of BRAF inhibitor combined with epidermal growth factor receptor (EGFR) inhibitor for patient-derived xenografts (PDXs) of BRAF mutant recurrent and metastatic colorectal cancer. Methods: From Jan. 2016 to Dec. 2016

a total of 34 colorectal cancer patients were performed CT guided biopsy because of recurrence or metastasis indicated by image examination. PDXs models of recurrent and metastatic colorectal cancer were established by biopsy specimen. Screened the BRAF V600E mutant and cultivated to F2 generation for drug administration. The experimental group: BRAF inhibitor (Group A)

EGFR inhibitor (Group B)

BRAF and EGFR inhibitor (Group C). The control group: placebo (Group D). After three weeks

the efficiency was evaluated by tumor inhibition rate. Results: Twenty-three of the patients were confirmed recurrence or metastasis by pathology. Sixteen PDXs models were established

with success rate of 69.6% (16/23). Four BRAF V600E mutant patients were screened and PDXs models were established. There was no obvious drug toxicity related death in experimental group. The tumor inhibition rate of experimental group was 21.57%、21.61% and 66.81%

respectively. Group C had the most significant reduction of tumor volume (P0.05). Conclusion: Combination of BRAF and EGFR inhibitor had high safety

feasibility and efficiency in PDXs of BRAF mutant recurrent and metastatic colorectal cancer.

关键词

Keywords

references

浏览量

2364

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

靶向治疗及免疫治疗联合化疗为产AFP阳性结肠癌患者带来显著获益1例病例报告并文献复习

Tepoxalin通过ABCB1影响结直肠癌细胞生长及耐药的分子机制研究

运动干预在结直肠癌患者全程管理中作用的研究进展及展望

基于人工智能辅助腹腔镜右半结肠癌根治术的手术技能评价

结直肠癌新辅助免疫治疗的进展与展望

BRAF和EGFR抑制剂联合用于BRAF突变型复发转移性结直肠癌PDXs模型的研究

BRAF inhibitor combined with EGFR inhibitor for PDXs model ofBRAFmutant recurrent and metastatic colorectal cancer

DOI：10.19401/j.cnki.1007-3639.2017.07.003

摘要

Abstract

关键词

Keywords

references